68.    Yuan C, Fan W, Zhou T, Sun D, Liu H, He Z, Wang Y: Ligand-free high loading capacity ursolic acid self-carried nanovesicles enable hepatocyte targeting via absorbing apolipoproteins. Int J Pharm 2023, 638:122931.

67.    Yang J, Jia L, He Z, Wang Y: Recent advances in SN-38 drug delivery system. Int J Pharm 2023, 637:122886.

66.    Li S, He Y, Sun D, Wang Z, Yu J, Ye J, He Z, Wang Y: Long Acting Ionically Paired Pamoate-based Suspension of Lurasidone: An exploration of Size Effects on in vitro Dissolution and in vivo Pharmacokinetic Behaviors. AAPS PharmSciTech 2023, 24(4):83.

65.    Jin C, Li J, Yang X, Zhou S, Li C, Yu J, Wang Z, Wang D, He Z, Jiang Y et al: Doxorubicin-isoniazid conjugate regulates immune response and tumor microenvironment to enhance cancer therapy. Int J Pharm 2023, 631:122509.

64.    Zhou S, Li J, Yu J, Wang Y, Wang Z, He Z, Ouyang D, Liu H, Wang Y: Tumor microenvironment adrenergic nerves blockade liposomes for cancer therapy. J Control Release 2022, 351:656-666.

63.    Xu X, Liu Y, Shao S, Li J, Xu Z, Yin Y, Zhao L, Wang Y, Liu D: Synthesis of Paclitaxel Derivatives for Remote Loading into Liposomes and Improved Therapeutic Effect. Molecules 2022, 27(22).

62.    Wang Z, Liu Y, Li S, Meng F, Yu J, Zhou S, Dong S, Ye J, Li L, Zhang C et al: Bioinspired Nanocomplexes Comprising Phenolic Acid Derivative and Human Serum Albumin for Cancer Therapy. Nano Lett 2022, 22(24):10040-10048.

61.    Wang Z, Li J, Lin G, He Z, Wang Y: Metal complex-based liposomes: Applications and prospects in cancer diagnostics and therapeutics. J Control Release 2022, 348:1066-1088.

60.    Wang Y, Yu J, Li D, Zhao L, Sun B, Wang J, Wang Z, Zhou S, Wang M, Yang Y et al: Paclitaxel derivative-based liposomal nanoplatform for potentiated chemo-immunotherapy. J Control Release 2022, 341:812-827.

59.   Liu Y, Li C, Xia H, Bi J, Guan R, Du X, Zhang H, He Z, Wang Y, Liu H: An injectable superior depot of Telratolimod inhibits post-surgical tumor recurrence and distant metastases. Acta Biomater 2022, 141:132-139.

58.   Li J, Cai W, Yu J, Zhou S, Li X, He Z, Ouyang D, Liu H, Wang Y: Autophagy inhibition recovers deficient ICD-based cancer immunotherapy. Biomaterials 2022, 287:121651.

57.   Jiang Q, Lu S, Xu X, Bai C, Yan Q, Fang M, Huang L, Jin C, Zhang Y, Sun J et al: Inhibition of alanine-serine-cysteine transporter 2-mediated auto-enhanced photodynamic cancer therapy of co-nanoassembly between V-9302 and photosensitizer. J Colloid Interface Sci 2022, 629(Pt B):773-784.

56.   Jia L, Liu Y, Li M, Wang Y, He Z: Direct comparison of two kinds of linoleic acid-docetaxel derivatives: in vitro cytotoxicity and in vivo antitumor activity. Drug Deliv Transl Res 2022, 12(5):1209-1218.

55.   Dong S, Zhang Y, Guo X, Zhang C, Wang Z, Yu J, Liu Y, Li C, Hu Y, Sun B et al: Glutathione Pulse Therapy: Promote Spatiotemporal Delivery of Reduction-Sensitive Nanoparticles at the "Cellular Level" and Synergize PD-1 Blockade Therapy. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2022, 9(27):e2202744.

54.   Dong S, Guo X, Han F, He Z, Wang Y: Emerging role of natural products in cancer immunotherapy. Acta Pharm Sin B 2022, 12(3):1163-1185.

53.   Zhou S, Li J, Yu J, Yang L, Kuang X, Wang Z, Wang Y, Liu H, Lin G, He Z et al: A facile and universal method to achieve liposomal remote loading of non-ionizable drugs with outstanding safety profiles and therapeutic effect. Acta Pharm Sin B 2021, 11(1):258-270.

52.   Zhou S, Li J, Yu J, Wang Y, Liu H, Lin G, He Z, Wang Y: Unique flower-like Cur-metal complexes loaded liposomes for primary and metastatic breast cancer therapy. Mater Sci Eng C Mater Biol Appl 2021, 121:111835.

51.   Yang Z, Zhao L, Wang X, He Z, Wang Y: Ratiometric Delivery of Mitoxantrone and Berberine Co-encapsulated Liposomes to Improve Antitumor Efficiency and Decrease Cardiac Toxicity. AAPS PharmSciTech 2021, 22(1):46.

50.   Wang X, Liu Y, Xu W, Jia L, Chi D, Yu J, Wang J, He Z, Liu X, Wang Y: Irinotecan and berberine co-delivery liposomes showed improved efficacy and reduced intestinal toxicity compared with Onivyde for pancreatic cancer. Drug Deliv Transl Res 2021.

49.   Li J, Zhou S, Yu J, Cai W, Yang Y, Kuang X, Liu H, He Z, Wang Y: Low dose shikonin and anthracyclines coloaded liposomes induce robust immunogenetic cell death for synergistic chemo-immunotherapy. J Control Release 2021, 335:306-319.

48.   Kuang X, Hu Y, Chi D, Zhang H, He Z, Jiang Y, Wang Y: Self-stabilized Pt(IV) amphiphiles by precise regulation of branch length for enhanced chemotherapy. Int J Pharm 2021:120923.

47.   Kuang X, Chi D, Li J, Guo C, Yang Y, Zhou S, Luo C, Liu H, He Z, Wang Y: Disulfide bond based cascade reduction-responsive Pt(IV) nanoassemblies for improved anti-tumor efficiency and biosafety. Colloids Surf B Biointerfaces 2021, 203:111766.

46.   Jin C, Wang Y, Li Y, Li J, Zhou S, Yu J, Wang Z, Yu Y, Zhang H, Wang D et al: Doxorubicin-Near infrared dye conjugate induces immunogenic cell death to enhance cancer immunotherapy. Int J Pharm 2021, 607:121027.

45.   Jia L, Liu Y, Li M, Wang Y, He Z: Direct comparison of two kinds of linoleic acid-docetaxel derivatives: in vitro cytotoxicity and in vivo antitumor activity. Drug Deliv Transl Res 2021.

44.   Jia L, Jiang Q, He Z, Wang Y: Characterization techniques: The stepping stone to liposome lyophilized product development. Int J Pharm 2021, 601:120519.

43.   Zhang R, Zhang Y, Zhang Y, Wang X, Gao X, Liu Y, Zhang X, He Z, Wang D, Wang Y: Ratiometric delivery of doxorubicin and berberine by liposome enables superior therapeutic index than DoxilⓇ. Asian J Pharm Sci 2020, 15(3):385-396.

42.   Yu J, Wang Y, Zhou S, Li J, Wang J, Chi D, Wang X, Lin G, He Z, Wang Y: Remote loading paclitaxel-doxorubicin prodrug into liposomes for cancer combination therapy. Acta Pharm Sin B 2020, 10(9):1730-1740.

41.   Yu J, Liu Y, Zhou S, Wang Y, Wang Y: Stimuli-responsive phospholipid-drug conjugates (PDCs)-based nanovesicles for drug delivery and theranostics. Int J Pharm 2020, 590:119920.

40.   Yang Z, Chi D, Wang Q, Guo X, Lv Q, Wang Y: Improved antitumor activity and tolerability of cabazitaxel derived remote-loading liposomes. Int J Pharm 2020, 589:119814.

39.   Wang Z, Lin X, Chi D, Xu Z, Lin G, Liu H, Sun J, He Z, Wang Y: Single-ligand dual-targeting irinotecan liposomes: Control of targeting ligand display by pH-responsive PEG-shedding strategy to enhance tumor-specific therapy and attenuate toxicity. Int J Pharm 2020, 587:119680.

38.   Na K, Liu K, Yu J, Wang X, Li M, Tian C, He H, He Y, Wang Y: A solvent-assisted active loading technology to prepare gambogic acid and all-trans retinoic acid co-encapsulated liposomes for synergistic anticancer therapy. Drug Deliv Transl Res 2020, 10(1):146-158.

37.   Yang W, Yang Z, Liu J, Liu D, Wang Y: Development of a method to quantify total and free irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) for pharmacokinetic and bio-distribution studies after administration of irinotecan liposomal formulation. Asian J Pharm Sci 2019, 14(6):687-697.

36.   Xue P, Wang J, Han X, Wang Y: Hydrophobic drug self-delivery systems as a versatile nanoplatform for cancer therapy: A review. Colloids Surf B Biointerfaces 2019, 180:202-211.

35.   Wang Z, Chi D, Wu X, Wang Y, Lin X, Xu Z, Liu H, Sun J, He Z, Wang Y: Tyrosine modified irinotecan-loaded liposomes capable of simultaneously targeting LAT1 and ATB(0,+) for efficient tumor therapy. J Control Release 2019, 316:22-33.

34.   Wang Y, Wang J, Yang L, Wei W, Sun B, Na K, Song Y, Zhang H, He Z, Sun J et al: Redox dual-responsive paclitaxel-doxorubicin heterodimeric prodrug self-delivery nanoaggregates for more effective breast cancer synergistic combination chemotherapy. Nanomedicine 2019, 21:102066.

33.   Liu J, Chi D, Pan S, Zhao L, Wang X, Wang D, Wang Y: Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent. Int J Pharm 2019, 557:264-272.

32.   Li M, Zhao L, Zhang T, Shu Y, He Z, Ma Y, Liu D, Wang Y: Redox-sensitive prodrug nanoassemblies based on linoleic acid-modified docetaxel to resist breast cancers. Acta Pharm Sin B 2019, 9(2):421-432.

31.   Zhou J, Zhu F, Li J, Wang Y: Concealed body mesoporous silica nanoparticles for orally delivering indometacin with chiral recognition function. Mater Sci Eng C Mater Biol Appl 2018, 90:314-324.

30.   Zhang T, Li M, Yang R, Zhang D, Guan J, Yu J, Yang B, Zhang H, Zhang S, Liu D et al: Therapeutic efficacy of lipid emulsions of docetaxel-linoleic acid conjugate in breast cancer. Int J Pharm 2018, 546(1-2):61-69.

29.  Lv Q, Yang X, Wang M, Yang J, Qin Z, Kan Q, Zhang H, Wang Y, Wang D, He Z: Mitochondria-targeted prostate cancer therapy using a near-infrared fluorescence dye-monoamine oxidase A inhibitor conjugate. J Control Release 2018, 279:234-242.

28.   Lv Q, Yang J, Zhang R, Yang Z, Yang Z, Wang Y, Xu Y, He Z: Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate. Mol Pharm 2018, 15(5):1842-1852.

27.   Lv Q, Wang D, Yang Z, Yang J, Zhang R, Yang X, Wang M, Wang Y: Repurposing antitubercular agent isoniazid for treatment of prostate cancer. Biomater Sci 2018, 7(1):296-306.

26.   Yang W, Wang Y, Fu Q, Guo Z, Sun B, Liu W, Liu Y, Mu S, Guo M, Li J et al: The role of particle size of glyburide crystals in improving its oral absorption. Drug Deliv Transl Res 2017, 7(3):428-438.

25.   Ren G, Jiang M, Guo W, Sun B, Lian H, Wang Y, He Z: Construction and cellular uptake behavior of redox-sensitive docetaxel prodrug-loaded liposomes. Pharmaceutical Development and Technology 2017, 23(1):22-32.

24.   Xue P, Liu D, Wang J, Zhang N, Zhou J, Li L, Guo W, Sun M, Han X, Wang Y: Redox-Sensitive Citronellol-Cabazitaxel Conjugate: Maintained in Vitro Cytotoxicity and Self-Assembled as Multifunctional Nanomedicine. Bioconjug Chem 2016, 27(5):1360-1372.

23.   Wang Z, Xie D, Liu H, Bao Z, Wang Y: Toxicity assessment of precise engineered gold nanoparticles with different shapes in zebrafish embryos. RSC Advances 2016, 6(39):33009-33013.

22.   Wang Y, Han X, Wang J, Wang Y: Preparation, characterization and in vivo evaluation of amorphous tacrolimus nanosuspensions produced using CO2-assisted in situ nanoamorphization method. Int J Pharm 2016, 505(1-2):35-41.

21.   Wang J, Xue P, Zhou J, Li L, Xu L, Wang Y: Comparison of two kinds of docetaxel-vitamin E prodrugs: In vitro evaluation and in vivo antitumor activity. International Journal of Pharmaceutics 2016, 505(1-2):352-360.

20.   Ren G, Liu D, Guo W, Wang M, Wu C, Guo M, Ai X, Wang Y, He Z: Docetaxel prodrug liposomes for tumor therapy: characterization, in vitro and in vivo evaluation. Drug Deliv 2016, 23(4):1272-1281.

19.   Ren G, Jiang M, Xue P, Wang J, Wang Y, Chen B, He Z: A unique highly hydrophobic anticancer prodrug self-assembled nanomedicine for cancer therapy. Nanomedicine 2016, 12(8):2273-2282.

18.   Li J, Fu Q, Liu X, Li M, Wang Y: Formulation of nimodipine nanocrystals for oral administration. Arch Pharm Res 2016, 39(2):202-212.

17.   Jiang M, Han X, Guo W, Li W, Chen J, Ren G, Sun B, Wang Y, He Z: Star-shape paclitaxel prodrug self-assembled nanomedicine: combining high drug loading and enhanced cytotoxicity. RSC Advances 2016, 6(110):109076-109082.

16.   Han X, Wang M, Ma Z, Xue P, Wang Y: A new approach to produce drug nanosuspensions CO 2 -assisted effervescence to produce drug nanosuspensions. Colloids and Surfaces B: Biointerfaces 2016, 143:107-110.

15.   Han X, Chen J, Jiang M, Zhang N, Na K, Luo C, Zhang R, Sun M, Lin G, Zhang R et al: Paclitaxel-Paclitaxel Prodrug Nanoassembly as a Versatile Nanoplatform for Combinational Cancer Therapy. ACS Appl Mater Interfaces 2016, 8(49):33506-33513.

14.   Wang D, Fu Q, Tang J, Hackett M, Wang Y, Liu F: Molecular-matched materials for anticancer drug delivery and imaging. Nanomedicine (Lond) 2015, 10(19):3003-3013.

13.   Qiu S, Liu K, Ma P, Wang M, Chen H, Xu X, Hao X, Wang Y: Simultaneous Analysis of Losartan Potassium and its Related Impurities and Degradation Products in Tablets Using HPLC. Current Pharmaceutical Analysis 2015, 11(1):25-34.

12.   Fu Q, Wang Y, Ma Y, Zhang D, Fallon JK, Yang X, Liu D, He Z, Liu F: Programmed Hydrolysis in Designing Paclitaxel Prodrug for Nanocarrier Assembly. Sci Rep 2015, 5:12023.

11.   Wang Y, Wang D, Fu Q, Liu D, Ma Y, Racette K, He Z, Liu F: Shape-controlled paclitaxel nanoparticles with multiple morphologies: rod-shaped, worm-like, spherical, and fingerprint-like. Mol Pharm 2014, 11(10):3766-3771.

10.   Wang Y, Liu D, Zheng Q, Zhao Q, Zhang H, Ma Y, Fallon JK, Fu Q, Haynes MT, Lin G et al: Disulfide bond bridge insertion turns hydrophobic anticancer prodrugs into self-assembled nanomedicines. Nano Lett 2014, 14(10):5577-5583.

9.   Leng D, Chen H, Li G, Guo M, Zhu Z, Xu L, Wang Y: Development and comparison of intramuscularly long-acting paliperidone palmitate nanosuspensions with different particle size. Int J Pharm 2014, 472(1-2):380-385.

8.   Wang Y, Liu H, Liu K, Sun J, He Z: Design and evaluation of enteric-coated tablets for rifampicin and isoniazid combinations. Pharm Dev Technol 2013, 18(2):401-406.

7.   Tang J, Wang Y, Wang D, Wang Y, Xu Z, Racette K, Liu F: Key structure of brij for overcoming multidrug resistance in cancer. Biomacromolecules 2013, 14(2):424-430.

6.   Wang Y, Xu H, Liu H, Wang Y, Sun J, He Z: Efficacy and biodistribution of tocopheryl polyethylene glycol succinate noncovalent functionalized single walled nanotubes loading doxorubicin in sarcoma bearing mouse model. J Biomed Nanotechnol 2012, 8(3):450-457.

5.   Wang Y, Sun J, Zhang T, Liu H, He F, He Z: Enhanced oral bioavailability of tacrolimus in rats by self-microemulsifying drug delivery systems. Drug Dev Ind Pharm 2011, 37(10):1225-1230.

4.   Wang Y, Sun J, Liu H, Liu J, Zhang L, Liu K, He Z: Predicting skin permeability using liposome electrokinetic chromatography. Analyst 2009, 134(2):267-272.

3.   Wang Y, Liu H, Sun J, He Z: Recent Applications of Monolithic Stationary Phases in Liquid Phase Separations. Current Pharmaceutical Analysis 2009, 5.

2.   Wang Y, Sun J, Liu H, Wang Y, He Z: Prediction of Human Drug Absorption Using Liposome Electrokinetic Chromatography. Chromatographia 2007, 65(3-4):173-177.

1.   Wang Y, Sun J, Liu H, He Z: Rapidly profiling blood-brain barrier penetration with liposome EKC. Electrophoresis 2007, 28(14):2391-2395.